1.75Open1.75Pre Close0 Volume10 Open Interest4.00Strike Price0.00Turnover179.59%IV5.89%PremiumAug 16, 2024Expiry Date1.43Intrinsic Value100Multiplier24DDays to Expiry0.32Extrinsic Value100Contract SizeAmericanOptions Type0.8140Delta0.1049Gamma3.06Leverage Ratio-0.0141Theta0.0018Rho2.49Eff Leverage0.0038Vega
Aurinia Pharmaceuticals Stock Discussion
Larger Image: tradingview.com...
$Aurinia Pharmaceuticals(AUPH.US)$
NEWS
Analysis Showing LUPKYNIS® is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation’s Spring Clinical Meeting 2024
Aurinia Pharmaceuticals (NASDAQ: AUPH) announced the cost-effectiveness of LUPKYNIS® (voclosporin) for treating lupus nephritis (LN) at the National Kidney Foundation Spring Clinical Meeting 2024. The updated analysis, consistent with a 2021 assessment, utilized the ICER AnalyticsTM LN model and found LUPKYNIS ...
Larger Image: tradingview.com...
$Aurinia Pharmaceuticals(AUPH.US)$
NEWS
The U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS® (voclosporin) Label to include Long-Term Data from the AURORA Clinical Program
The FDA has approved an updated label for LUPKYNIS, a drug by Aurinia Pharmaceuticals (NASDAQ: AUPH), including long-term data from the AURORA Clinical Program, showing sustained complete renal response through three years. The label now indicates that monthly kidney function assessment is no longer required af...
No comment yet